Atlanta, GA, March 06, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to proactively improve financial performance, announced today it has signed a contract with a 1,600-bed health system in New Jersey. The organization will use eValuator’s automated pre-bill coding analysis platform to help improve revenue integrity and financial performance from inpatient and outpatient care.
eValuator’s pre-bill code analysis makes it easy for providers to identify, quantify and expedite correction of coding issues with the highest impact on revenue integrity. With eValuator, providers can optimize financial performance from their inpatient, outpatient, and Pro-Fee encounters through one platform without billing delays.
“Adding another academic medical center-based health system in New Jersey as a partner is especially fulfilling,” stated Ben Stilwill, President, Streamline Health. “Given the complex care they provide, it’s crucial to ensure they’re reimbursed fully and accurately. Using eValuator to optimize coding integrity prior to billing will help them focus on— and better fund— their mission of delivering quality care to their community.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) is dedicated to helping providers ensure they’re accurately paid for the care they provide. We deliver integrated solutions, technology-enabled services, and analytics that drive compliant revenue, leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
To Learn More
Media
David Kosloski
Vice President, Marketing & Communications
651.308.1395
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors
Jacob Goldberger
Director, Investor Relations and FP&A
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.98 |
| Daily Change: | -0.42 -12.35 |
| Daily Volume: | 32,177 |
| Market Cap: | US$188.690M |
October 08, 2024 July 16, 2024 July 02, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
